• Publications
  • Influence
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
TLDR
A genomic predictor combining ER status, predicted Chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy. Expand
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
TLDR
A 30-probe set pharmacogenomic predictor predicted pCR to T/FAC chemotherapy with high sensitivity and negative predictive value. Expand
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth
TLDR
Adding trastuzumab to chemotherapy, as used in this trial, significantly increased pathologic complete response (pCR) rate without clinical congestive heart failure, according to the small sample size. Expand
Genomic index of sensitivity to endocrine therapy for breast cancer.
TLDR
The SET index of ER-related transcription predicted survival benefit from adjuvant endocrine therapy, not inherent prognosis, and prior chemotherapy seemed to enhance the efficacy of adjuant endocrine Therapy related to SET index. Expand
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
TLDR
It is shown that genomic predictor accuracy is determined largely by an interplay between sample size and classification difficulty, and several statistically equally good predictors can be developed for any given classification problem. Expand
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
TLDR
Weekly docetaxel and trastuzumab is an active combination for treating patients with HER-2-overexpressing metastatic breast cancer and serum Her-2 ECD testing may be a promising method for monitoring patients on trastzumab-based therapy. Expand
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
TLDR
The change in schedule of paclitaxel from once every 3 weeks to a more frequent administration significantly improved the ability to eradicate invasive cancer in the breast and lymph nodes. Expand
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
TLDR
Different biological processes were associated with prognosis and chemotherapy response in ER-positive and ER-negative breast cancers. Expand
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
TLDR
Weekly paclitaxel induces transient increase in IL-10 levels whereas every 3-week higher dose treatments induce IL-8 and IL-6 in the plasma, which correlate with joint pain and flu-like symptoms. Expand
Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer
TLDR
EBI significantly increased CNS metastasis-free interval with a beneficial effect that was significant in males, patients with weight loss less than 6%, squamous cell histology or responders, and patients with good performance status or no prior therapy. Expand
...
1
2
3
4
5
...